TACE联合PEIT治疗转移性肝癌

 目的 观察经导管肝动脉内化疗栓塞(TACE)联合无水酒精瘤内注射治疗肝转移癌的疗效。 方法 治疗组28例转移性肝癌先行TACE治疗1~2次后，在B型超声定位和动态观察下,对直径<10cm的肝转移瘤,行经皮肝穿刺瘤内无水酒精注射治疗(Percutaneous ethanol injection therapy, PEIT)3～10次。对照组29例行全身化疗3~4周期。观察两组不良反应并随访统计半年、1年生存率。 结果 治疗组半年生存率100%,1年生存率85.7%,无严重并发症发生。对照组半年生存率82.8％，1年生存率48.3%，两组1年生存率比较差异有统计学意义。 结论 TACE联合PEIT治疗转移性肝癌可提高肝转移癌的治疗有效率、且创伤性小，患者耐受性好，但复发的问题有待进一步解决。

Treatment of TACE Combined with PEIT for Metastatic Liver Cancer

Objective To observe the efficiency of the treatment of transcatheter arterial chemoembolization (TACE) combined with percutaneous ethanol injection treatment (PEIT) for metastatic liver cancer. Methods 28 cases of metastatic liver cancer in the treatment group first accepted TACE treatment 1~2 times,and then accepted percutaneous ethanol injection therapy(PEIT)3~10 times.29 cases of metastatic liver cancer in the control group accepted full body routine chemotherapy for 3~4 cycles. Adverse reactions of two groups were observed and follow-up statistician the survival rate of half a year and 1 year for each group. Results In the treatment group, the survival rate of half a year and 1 year was 100% and 85.7%, respectively. For the control group the survival rate of half a year and 1 year was 82.8% and 48.3%, respectively. Thus the difference in the survival rate of 1 year for the two groups was significant. Conclusion The treatment of TACE combined with PEIT for the metastatic liver cancer may improve the efficiency,and was well tolerated by the patients, but the problem of recurrence is not yet to be solved.